Sartorius Stedim Biotech S.A. (SRTOY) Comparison with companies in other sectors?

Sartorius Stedim Biotech S.A. has a share price of 9.73B. You can analyze Sartorius Stedim Biotech S.A. (SRTOY) competitors across different market sectors through stock heatmaps.

What are SRTOY's NET and operating margins?

Sartorius Stedim Biotech S.A. (SRTOY) operating margin is around 0.16, and net profit margin is approximately 0.07 as of the latest reports.

In what way does SRTOY's earnings per share (EPS) trend reflect its financial momentum?

Sartorius Stedim Biotech S.A. (SRTOY) EPS is 0.25 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Sartorius Stedim Biotech S.A. is 87.38, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Sartorius Stedim Biotech S.A.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Sartorius Stedim Biotech S.A. like P/E which is 885.02, P/B which is 45.52, and PEG which is 62.41. Compare them with sector averages to evaluate if the stock is priced fairly.

Sartorius Stedim Biotech S.A.

SRTOY•PNK

Healthcare

Medical - Instruments & Supplies

$21.84

$-0.38(-1.70%)

Fundamental Analysis of Sartorius Stedim Biotech S.A. (SRTOY)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$0.25

P/E Ratio

87.38

ROE

0.05%

Net Margin

0.07%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$212.54B

Shares OutstandingTotal number of shares issued

$9.73B

Book Value/ShareNet worth per share

$4.12

Revenue/ShareAnnual revenue per share

$2.94

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.25

Net MarginNet income as percentage of revenue

7.15%

Operating MarginOperating income as percentage of revenue

15.61%

ROEReturn on shareholders' equity

5.19%

ROAReturn on total assets

2.46%

ROCEReturn on capital employed

6.08%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$0.60

Cash/ShareCash and equivalents per share

$0.75

FCF YieldFree cash flow as percentage of market cap

0.32%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$0.06

Dividend YieldAnnual dividend as percentage of stock price

0.35%

Financial Ratios Analysis data is not available for SRTOYFinancial Ratios Analysis details for SRTOY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for SRTOYSector Benchmarking details for SRTOY are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Sartorius Stedim Biotech S.A. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Sartorius Stedim Biotech S.A.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Sartorius Stedim Biotech S.A.'s unique business strengths and challenges.

Key Financial Metrics for Sartorius Stedim Biotech S.A.

For Sartorius Stedim Biotech S.A., essential financial indicators include EPS 0.25, PE 87.38, and ROE 0.05. These key ratios reveal insights into Sartorius Stedim Biotech S.A.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Sartorius Stedim Biotech S.A. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Sartorius Stedim Biotech S.A.

Metrics like Net Margin 7.15% and ROA 2.46% shed light on how well Sartorius Stedim Biotech S.A. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Sartorius Stedim Biotech S.A. can sustain its operations and continue growing in the future.

Valuation and Market Position of Sartorius Stedim Biotech S.A.

Using ratios such as P/B Ratio 45.52 and PEG Ratio 62.41, investors can assess whether Sartorius Stedim Biotech S.A. is appropriately valued based on its financials and growth potential. These figures, combined with Sartorius Stedim Biotech S.A.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Sartorius Stedim Biotech S.A.

Financial health indicators, such as Debt/Equity Ratio 0.74 and Cash Flow $0.60, provide a snapshot of Sartorius Stedim Biotech S.A.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Sartorius Stedim Biotech S.A., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Sartorius Stedim Biotech S.A.

Investing in Sartorius Stedim Biotech S.A. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Sartorius Stedim Biotech S.A. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;